Alzinova presents at CTAD conference
Date: 2022-11-30
This week, Alzinova presents data for the Company's preclinical antibody candidate ALZ-201 at the conference in a poster presentation at the important scientific conference CTAD – , Clinical Trials in Alzheimer's Disease.
The conference is held in San Francisco from 29 November to 2 December. Alzinova’s Chief Scientific Officer Anders Sandberg will summarise the antibody’s unique binding profile in a poster presentation titled “ALZ-201, a monoclonal antibody therapy for specific neutralization of toxic amyloid-β in Alzheimer’s disease”.